公开(公告)号：EP1301528A2

公开(公告)日：2003-04-16

申请号：EP01959046.2

申请日：2001-07-19

申请人： SCHERING CORPORATION ,  CORVAS INTERNATIONAL, INC.

发明人： SAKSENA, Anil, K. ,  GIRIJAVALLABHAN, Viyyoor, Moopil ,  LOVEY, Raymond, G. ,  JAO, Edwin, E. ,  BENNETT, Frank ,  MCCORMICK, Jinping ,  WANG, Haiyan ,  PIKE, Russell, E. ,  BOGEN, Stephane, L. ,  LIU, Yi-Tsung ,  ARASAPPAN, Ashok ,  PAREKH, Tejal ,  PINTO, Patrick, A. ,  NJOROGE, F., George ,  GANGULY, Ashit, K. ,  BRUNCK, Terence, K. ,  KEMP, Scott, Jeffrey ,  LEVY, Odile, Esther ,  LIM-WILBY, Marguerita

IPC分类号： C07K7/06 ,  C07K14/18 ,  A61K38/55 ,  A61P31/14

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K7/02

摘要： The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

摘要翻译： 本发明公开了具有HCV蛋白酶抑制活性的新型肽化合物以及制备该化合物的方法。 在另一个实施方案中，本发明公开了包含此类肽的药物组合物以及使用它们治疗与HCV蛋白酶相关的病症的方法。

公开(公告)号：EP1121369B1

公开(公告)日：2004-12-08

申请号：EP99970662.5

申请日：1999-10-14

申请人： SCHERING CORPORATION

发明人： GANGULY, Ashit, K. ,  MCCORMICK, Jinping ,  LOVEY, Raymond, G. ,  BENNETT, Frank ,  SAKSENA, Anil, K. ,  GIRIJAVALLABHAN, Viyyoor, M.

IPC分类号： C07H19/056 ,  A61K31/70

CPC分类号： C07H19/056

摘要： A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula (I) and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.

公开(公告)号：EP1121369A1

公开(公告)日：2001-08-08

申请号：EP99970662.5

申请日：1999-10-14

申请人： SCHERING CORPORATION

发明人： GANGULY, Ashit, K. ,  MCCORMICK, Jinping ,  LOVEY, Raymond, G. ,  BENNETT, Frank ,  SAKSENA, Anil, K. ,  GIRIJAVALLABHAN, Viyyoor, M.

IPC分类号： C07H19/056 ,  A61K31/70

CPC分类号： C07H19/056

摘要： A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula (I) and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.

摘要翻译： 一种治疗患有慢性丙型肝炎感染的患者以根除可检测的HCV-RNA的方法，涉及组合疗法，使用治疗有效量的式（I）的利巴韦林衍生物和治疗有效量的干扰素-α，时间为20 长达80周。

公开(公告)号：EP1282632A1

公开(公告)日：2003-02-12

申请号：EP01928662.4

申请日：2001-04-18

申请人： SCHERING CORPORATION

发明人： GANGULY, Ashit, K. ,  MCCORMICK, Jinping ,  LOVEY, Raymond, G. ,  BENNETT, Frank ,  SAKSENA, Anil, K. ,  GIRIJAVALLABHAN, Viyyoor, M.

IPC分类号： C07H19/056 ,  A61K31/7056 ,  A61P31/12

CPC分类号： C07H19/056 ,  Y10S514/894

摘要： Ribavirin derivatives represented by the formula (II), pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula (II) for the preparation of a medicament for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula (II) are disclosed.